Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Always Active
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.

David Shlaes

22 August 2019

Dr Shlaes, author of Antibiotics, The Perfect Storm (Springer) and The Drug Makers (Lulu), has had a thirty-year career in anti-infectives spanning academia and industry with a long-standing scientific interest in antimicrobial resistance.

He trained in infectious diseases at Case Western Reserve University in Cleveland. He then taught, maintained an active research program, cared for patients and eventually became Professor of Medicine there. In 1996, Dr Shlaes left academia to become Vice President for Infectious Diseases at Wyeth Pharmaceuticals where he was an important leader in the development of tigecycline. In 1998, he was the cover feature in the April issue of Business Week dedicated to antibiotics research. He also was a member of the Forum for Emerging Infections of the National Academy of Sciences for seven years. In 2002, Dr. Shlaes became Executive Vice President, Research and Development for Idenix, Pharmaceuticals, a company located in Cambridge, MA, focused on the discovery and development of antivirals. In 2005, he established a consulting company. During his consulting years, he contributed in significant ways to the development of avibactam and the discovery and development of lefamulin. During his working career, he lived in Paris, France for several years.

Dr Shlaes has since retired from Anti-infectives Consulting. He remains an Editor for Antimicrobial Agents and Chemotherapy, writes a blog – Antibiotics the Perfect Storm, remains active in antibiotic policy areas and spends a good deal of time in France.